CoChat

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis

Open access
Dand, Nick, Duckworth, Michael, Baudry, David, Russell, Alice, Curtis, Charles J., Lee, Sang Hyuck, Evans, Ian, Mason, Kayleigh J., Alsharqi, Ali, Becher, Gabrielle, Burden, A. David, Goodwin, Richard G., McKenna, Kevin, Murphy, Ruth, Perera, Gayathri K., Rotarescu, Radu, Wahie, Shyamal, Wright, Andrew, Reynolds, Nick J., Warren, Richard B., Griffiths, Christopher E.M., Smith, Catherine H., Simpson, Michael A., Barker, Jonathan N., Benham, Marilyn, Hussain, Sagair, Kirby, Brian, Lawson, Linda, McElhone, Kathleen, Ormerod, Anthony, Owen, Caroline, Barnes, Michael R., Di Meglio, Paola, Emsley, Richard, Evans, Andrea, Payne, Katherine, Stocken, Deborah · 2019 · Journal of Allergy and Clinical Immunology
Cited by 182

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND Biologic therapies can be highly effective for the treatment of severe psoriasis, but response for individual patients can vary according to drug. Predictive biomarkers to guide treatment selection could improve patient outcomes and treatment cost-effectiveness. OBJECTIVE We sought to test whether HLA-C*06:02, the primary genetic susceptibility allele for psoriasis, predisposes patients to respond differently to the 2 most commonly prescribed biologics for psoriasis: adalimumab (anti-TNF-α) and ustekinumab (anti-IL-12/23). METHODS This study uses a national psoriasis registry that includes longitudinal treatment and response observations and detailed clinical data. HLA alleles were imputed from genome-wide genotype data for 1326 patients for whom 90% reduction in Psoriasis Area and Severity Index score (PASI90) response status was observed after 3, 6, or 12 months of treatment. We developed regression models of PASI90 response, examining the interaction between HLA-C*06:02 and drug type (adalimumab or ustekinumab) while accounting for potentially confounding clinical variables. RESULTS HLA-C*06:02-negative patients were significantly more likely to respond to adalimumab than ustekinumab at all time points (most strongly at 6 months: odds ratio [OR], 2.95; P = 5.85 × 10-7), and the difference was greater in HLA-C*06:02-negative patients with psoriatic arthritis (OR, 5.98; P = 6.89 × 10-5). Biologic-naive patients who were HLA-C*06:02 positive and psoriatic arthritis negative demonstrated significantly poorer response to adalimumab at 12 months (OR, 0.31; P = 3.42 × 10-4). Results from HLA-wide analyses were consistent with HLA-C*06:02 itself being the primary effect allele. We found no evidence for genetic interaction between HLA-C*06:02 and ERAP1. CONCLUSION This large observational study suggests that reference to HLA-C*06:02 status could offer substantial clinical benefit when selecting treatments for severe psoriasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2018.11.038

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 182

Metadata

Authors
Dand, N., Duckworth, M., Baudry, D., Russell, A., Curtis, C. J., Lee, S. H., Evans, I., Mason, K. J., Alsharqi, A., Becher, G., Burden, A. D., Goodwin, R. G., McKenna, K., Murphy, R., Perera, G. K., Rotarescu, R., Wahie, S., Wright, A., Reynolds, N. J., Warren, R. B., Griffiths, C. E. M., Smith, C. H., Simpson, M. A., Barker, J. N., Benham, M., Hussain, S., Kirby, B., Lawson, L., McElhone, K., Ormerod, A., Owen, C., Barnes, M. R., Di Meglio, P., Emsley, R., Evans, A., Payne, K., & Stocken, D.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2019-06
Volume
143
Issue
6
Pages
2120-2130
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2903830162
Cited by
182
References
5
FWCI
6.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.